PubMed Digest — May 2026: BPC-157, MOTS-c, LL-37 Research Updates
Recent peer-reviewed publications on BPC-157, MOTS-c, GHK-Cu, Epitalon, and LL-37 — systematic reviews, mechanistic studies, and antimicrobial advances.
Last reviewed
A roundup of notable peer-reviewed publications on the peptides covered by PeptidesBeat, published or indexed in the first half of 2026.
BPC-157: Two new systematic reviews
The growing clinical interest in BPC-157 is reflected in two recent systematic reviews.
A narrative review published in Current Reviews in Musculoskeletal Medicine — titled “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing” (Aug 2025) — examined the available evidence for BPC-157 in tendon, ligament, and muscle injuries. The review concluded that while preclinical data shows promise, human clinical trial evidence remains limited and the risk profile is not yet fully characterized.
An independent systematic review in HSS Journal — “Emerging Use of BPC-157 in Orthopaedic Sports Medicine” (Jul 2025) — reached similar conclusions, finding that BPC-157’s adoption in sports medicine is outpacing the evidence base. The authors noted that most published studies are animal models and called for randomized controlled trials in human subjects.
A broader review in Pharmaceuticals — “Multifunctionality and Possible Medical Application of the BPC 157 Peptide” (Jan 2025) — catalogued BPC-157’s reported effects across organ systems, including gastrointestinal, cardiovascular, and musculoskeletal targets, while also surveying the patent landscape.
MOTS-c: Lung injury mechanisms
Two new studies on the mitochondrial-derived peptide MOTS-c explore its role in lung injury.
Research published in the American Journal of Respiratory Cell and Molecular Biology (Sep 2025) found that MOTS-c promotes glycolysis via the AMPK-HIF-1α-PFKFB3 pathway to ameliorate cardiopulmonary bypass-induced lung injury — identifying a specific molecular mechanism for the peptide’s protective effects.
A related study in Free Radical Biology and Medicine (Jan 2025) demonstrated that MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction.
GHK-Cu: Anti-inflammatory filler development
Research in Colloids and Surfaces B: Biointerfaces (Jul 2025) described an injectable hydroxyapatite microsphere filler loaded with GHK-Cu for anti-inflammatory and antioxidant applications — a formulation approach that could bridge the gap between cosmetic and therapeutic use of the copper tripeptide.
Epitalon: Comprehensive overview
The International Journal of Molecular Sciences published an overview of Epitalon (Mar 2025), characterizing the synthetic pineal tetrapeptide’s reported biological activities, including telomerase activation, melatonin regulation, and potential anti-aging effects. The review noted that while preclinical data is encouraging, human studies remain scarce.
LL-37: Antimicrobial advances
Multiple recent publications on the human cathelicidin LL-37 reflect sustained research interest in host-defense peptides. An update in Inflammation Research (Feb 2025) examined how LL-37 may prevent local infection spread through multiple mechanisms. A review in International Immunopharmacology (Feb 2025) covered LL-37’s role in periodontitis.
Broader reviews in the International Journal of Molecular Sciences (Aug 2025) and ACS Biomaterials Science & Engineering (May 2025) covered LL-37 modifications and antimicrobial potential against multidrug-resistant pathogens.
PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.
Educational content, not medical advice. © 2026 PeptidesBeat.